Allotex Inc. and SpA, a Boston, MA- and Milan, Italy-based biologics and device company specializing in vision correction therapies, received an investment from Junson Capital.
Junson Capital has joined the existing investors including KCK MedTech, Panakes, Supernova Invest, and Exor Ventures to complete the Series B financing.
The company intends to use the capital for the expansion of its production facility in preparation for market introduction and US clinical trials.
Led by Dr. David Muller, Founder and CEO, Allotex is a biologics and device company that provides an approach that uses laser-shaped human corneal allografts to reshape the cornea for the treatment of presbyopia, restoring lost reading vision which is caused by the natural aging process. With a commitment to advancing vision correction, it is dedicated to improving the lives of individuals affected by presbyopia and other refractive disorders of the human eye.
FinSMEs
04/11/2023